© 2025
In touch with the world ... at home on the High Plains
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
KZNA-FM 90.5 serving northwest Kansas is operating at just 10% power using a back up transmitter while work continues to install a new transmitter. It is hoped that this work will completed on Thursday with KZNA back to its full 100,000 watts of power with a state of the art transmitter to serve the area for many years to come.
If you can't receive KZNA at its reduced power, you can listen via the digital stream directly above or on the HPPR mobile app. For questions please contact station staff at (800) 678-7444 or by emailing hppr@hppr.org

FDA recalls a blood pressure and PTSD medication that may contain a cancer-causing chemical

Sign up for TPR Today, Texas Public Radio's newsletter that brings our top stories to your inbox each morning.

A blood pressure medication that is also sometimes used to treat nightmares related to PTSD has been recalled by its manufacturer. Teva Pharmaceuticals recalled more than half a million bottles of Prazosin Hydrochloride because the pills may contain higher levels of a chemical that's been linked with the development of cancer than is considered safe.

The recall includes bottles containing 1 mg, 2 mg, and 5 mg capsules. If you take Prazosin Hydrochloride for high blood pressure or PTSD, check the lot number on your bottle to see if it's been recalled.

The following medication lots are being recalled:

Prazosin Hydrochloride, 1 mg capsules, recall number D-0104-2026 (181,659 bottles)

NDC number NDC 0093-4067-01 (100 capsules)

  • 3010544A, Exp Date: 10/2025
  • 3010545A, Exp Date: 10/2025
  • 3010567A, Exp Date: 12/2025
  • 3010590A, Exp Date: 02/2026
  • 3010601A, Exp Date: 03/2026
  • 3010602A, Exp Date: 03/2026
  • 3010603A, Exp Date: 03/2026
  • 3010652A, Exp Date: 07/2026
  • 3010670A, Exp Date: 07/2026
  • 3010671A, Exp Date: 07/2026
  • 3010678A, Exp Date: 08/2026
  • 3010700A, Exp Date: 08/2026
  • 3010701A, Exp Date: 08/2026

NDC 0093-4067-10 (1,000 capsules)

  • 3010440A, Exp Date: 12/2025
  • 3010672A, Exp Date: 07/2026

Prazosin Hydrochloride, 2 mg capsules, recall number D-0105-2026 (291,512 bottles)

NDC 0093-4068-01 (100 capsules)

  • 3010398A, Exp Date: 12/2025
  • 3010399A, Exp Date: 12/2025
  • 3010400A, Exp Date: 12/2025
  • 3010401A, Exp Date: 12/2025
  • 3010353A, Exp Date: 12/2025
  • 3010439A, Exp Date: 01/2026
  • 3010388A, Exp Date: 01/2026
  • 3010526A, Exp Date: 03/2026
  • 3010527A, Exp Date: 03/2026
  • 3010591A, Exp Date: 07/2026
  • 3010343A, Exp Date: 10/2025
  • 3010352A, Exp Date: 11/2025
  • 3010468A, Exp Date: 02/2026
  • 3010469A, Exp Date: 02/2026
  • 3010461A, Exp Date: 02/2026
  • 3010629A, Exp Date: 09/2026
  • 3010653A, Exp Date: 01/2027
  • 3010654A, Exp Date: 02/2027
  • 3010679A, Exp Date: 02/2027
  • 3010702A, Exp Date: 02/2027
  • 3010547A, Exp Date: 04/2026

NDC 0093-4068-10 (1,000 capsules)

  • 3010402A Exp Date: 02/2028
  • 3010593A, Exp Date: 07/2026
  • 3010610A, Exp Date: 09/2026

Prazosin Hydrochloride, 5 mg capsules, recall number D-0106-2026 (107,673 bottles)

NDC 0093-4069-01 (100 capsules)

  • 3010403A, Exp Date: 02/2026
  • 3010385A, Exp Date: 02/2026
  • 3010404A, Exp Date: 02/2026
  • 3010405A, Exp Date: 03/2026
  • 3010510A, Exp Date: 03/2026
  • 3010528A, Exp Date: 03/2026
  • 3010354A, Exp Date: 03/2026
  • 3010592A, Exp Date: 08/2026
  • 3010605A, Exp Date: 08/2026
  • 3010611A, Exp Date: 08/2026
  • 3010612A, Exp Date: 08/2026
  • 3010655A, Exp Date: 02/2027
  • 3010703A, Exp Date: 02/2027

NDC 0093-4069-52 (250 capsules)

  • 3010430A, Exp Date: 11/2025
  • 3010613A, Exp Date: 08/2026

NDC 0093-4069-05 (500 capsules)

  • 3010406A, Exp Date: 02/2026

The chemicals of concern in this recall are called nitrosamines, which form naturally in the environment. They can be found in safe amounts in drinking water and food. However, they can form in quantities that are potentially carcinogenic in medications during manufacturing. According to the FDA, the recall was triggered by tests that indicated that the level of a certain type of nitrosamine was above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above-specified lots.

The FDA has classified the recall as a Class II, which is "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

If so, please contact your doctor for further instructions.

Copyright 2025 KSTX News

Bonnie Petrie
Bonnie Petrie covers bioscience and medicine for Texas Public Radio.